Efficacy and Safety of Albuterol Multidose Dry Powder Inhaler (MDPI) Versus Placebo in Children With Asthma

After a 14-day run-in period during which patients continued their current asthma therapy and received single-blind placebo MDPI, patients were randomized to albuterol MDPI, 90 mcg/inhalation, 2 inhalations 4 times daily (total daily dose, 720 mcg) or placebo for 3 weeks.

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 137; no. 2; p. AB209
Main Authors LaForce, Craig, MD, CPI, Taveras, Herminia, PhD, MPH, Iverson, Harald, PhD, Shore, Paul, MD, MS, Shah, Tushar P., MD
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Inc 01.02.2016
Elsevier Limited
Subjects
Allergy and Immunology
Asthma
Pediatrics
Online AccessGet full text

Cover

More Information
Summary:After a 14-day run-in period during which patients continued their current asthma therapy and received single-blind placebo MDPI, patients were randomized to albuterol MDPI, 90 mcg/inhalation, 2 inhalations 4 times daily (total daily dose, 720 mcg) or placebo for 3 weeks.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2015.12.1124